Play all audios:
![ABSTRACT Biodistribution of chimeric mouse/human monoclonal antibody against non-specific cross-reacting antigen (chNCA Ab) was studied in athymic mice and patients with metastatic bone disease. 99mTc-chNCA Ab showed a high labelling efficiency, stability and also a high binding ratio to human granulocytes. Since NCA showed cross-reactivity with carcinoembryonic antigen (CEA), animal experiments showed that 99mTc-chNCA Ab was accumulated in the xenografted tumour which expressed CEA, suggesting the preserved immunoreactivity of labelled materials. In the clinical study, injected 99mTc-chNCA Ab formed a high molecular weight complex immediately after intravenous administration and was trapped mainly in liver. The first-phase plasma half-life was 6.4 +/- 1.1 min. None of the patients showed adverse reaction or human antimurine or anti-chimeric antibody in their serum. 99mTc-chNCA Ab demonstrated remarkably different biodistribution between patients and the animal model and showed different pharmacokinetics from other murine and chimeric Abs reported previously. For safety HPLC analysis should be performed before clinical radioimmunodetection or radioimmunotherapy by incubating radiolabelled MAb with human serum under strict conditions. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS EFFICIENT BONE MARROW IRRADIATION AND LOW UPTAKE BY NON-HAEMATOLOGICAL ORGANS WITH AN YTTRIUM-90-ANTI-CD66 ANTIBODY PRIOR TO HAEMATOPOIETIC STEM CELL TRANSPLANTATION Article Open access 12 June 2024 PET IN VIVO GENERATORS 134CE AND 140ND ON AN INTERNALIZING MONOCLONAL ANTIBODY PROBE Article Open access 09 March 2022 DEVELOPMENT OF [211AT]ASTATINE-BASED ANTI-CD123 RADIOIMMUNOTHERAPY FOR ACUTE LEUKEMIAS AND OTHER CD123+ MALIGNANCIES Article 26 April 2022 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Nuclear Medicine, Gunma University School of Medicine, Maebashi, Japan N Oriuchi Authors * N Oriuchi View author publications You can also search for this author inPubMed Google Scholar * N Watanabe View author publications You can also search for this author inPubMed Google Scholar * S Sugiyama View author publications You can also search for this author inPubMed Google Scholar * T Higuchi View author publications You can also search for this author inPubMed Google Scholar * K Imai View author publications You can also search for this author inPubMed Google Scholar * H Yamanaka View author publications You can also search for this author inPubMed Google Scholar * M Hashimoto View author publications You can also search for this author inPubMed Google Scholar * H Kanda View author publications You can also search for this author inPubMed Google Scholar * K Endo View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Oriuchi, N., Watanabe, N., Sugiyama, S. _et al._ Different biodistribution of 99mTc-labelled chimeric mouse-human monoclonal antibody between athymic mice model and human. _Br J Cancer_ 73, 1466–1472 (1996). https://doi.org/10.1038/bjc.1996.278 Download citation * Issue Date: 01 June 1996 * DOI: https://doi.org/10.1038/bjc.1996.278 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41409-024-02317-z/MediaObjects/41409_2024_2317_Fig1_HTML.png)
ABSTRACT Biodistribution of chimeric mouse/human monoclonal antibody against non-specific cross-reacting antigen (chNCA Ab) was studied in athymic mice and patients with metastatic bone
disease. 99mTc-chNCA Ab showed a high labelling efficiency, stability and also a high binding ratio to human granulocytes. Since NCA showed cross-reactivity with carcinoembryonic antigen
(CEA), animal experiments showed that 99mTc-chNCA Ab was accumulated in the xenografted tumour which expressed CEA, suggesting the preserved immunoreactivity of labelled materials. In the
clinical study, injected 99mTc-chNCA Ab formed a high molecular weight complex immediately after intravenous administration and was trapped mainly in liver. The first-phase plasma half-life
was 6.4 +/- 1.1 min. None of the patients showed adverse reaction or human antimurine or anti-chimeric antibody in their serum. 99mTc-chNCA Ab demonstrated remarkably different
biodistribution between patients and the animal model and showed different pharmacokinetics from other murine and chimeric Abs reported previously. For safety HPLC analysis should be
performed before clinical radioimmunodetection or radioimmunotherapy by incubating radiolabelled MAb with human serum under strict conditions. Access through your institution Buy or
subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online
access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which
are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS
EFFICIENT BONE MARROW IRRADIATION AND LOW UPTAKE BY NON-HAEMATOLOGICAL ORGANS WITH AN YTTRIUM-90-ANTI-CD66 ANTIBODY PRIOR TO HAEMATOPOIETIC STEM CELL TRANSPLANTATION Article Open access 12
June 2024 PET IN VIVO GENERATORS 134CE AND 140ND ON AN INTERNALIZING MONOCLONAL ANTIBODY PROBE Article Open access 09 March 2022 DEVELOPMENT OF [211AT]ASTATINE-BASED ANTI-CD123
RADIOIMMUNOTHERAPY FOR ACUTE LEUKEMIAS AND OTHER CD123+ MALIGNANCIES Article 26 April 2022 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Nuclear Medicine, Gunma University
School of Medicine, Maebashi, Japan N Oriuchi Authors * N Oriuchi View author publications You can also search for this author inPubMed Google Scholar * N Watanabe View author publications
You can also search for this author inPubMed Google Scholar * S Sugiyama View author publications You can also search for this author inPubMed Google Scholar * T Higuchi View author
publications You can also search for this author inPubMed Google Scholar * K Imai View author publications You can also search for this author inPubMed Google Scholar * H Yamanaka View
author publications You can also search for this author inPubMed Google Scholar * M Hashimoto View author publications You can also search for this author inPubMed Google Scholar * H Kanda
View author publications You can also search for this author inPubMed Google Scholar * K Endo View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND
PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Oriuchi, N., Watanabe, N., Sugiyama, S. _et al._ Different biodistribution of 99mTc-labelled chimeric mouse-human
monoclonal antibody between athymic mice model and human. _Br J Cancer_ 73, 1466–1472 (1996). https://doi.org/10.1038/bjc.1996.278 Download citation * Issue Date: 01 June 1996 * DOI:
https://doi.org/10.1038/bjc.1996.278 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not
currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative